Key Dates

Related Announcements

PAR-21-166 - Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to correct the expiration date and to add clarification to the Research Strategy section of Funding Opportunity Announcement (FOA) PAR-21-166, "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)".

The following sections of PAR-21-166 have been modified:

Currently Reads:

Part 1. Overview Information

Key Dates

Posted Date

March 25, 2021

Open Date (Earliest Submission Date)

May 05, 2021

Letter of Intent Due Date(s)

Not Applicable

The following table includes NIH standard due dates marked with an asterisk.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

January 08, 2024

Due Dates for E.O. 12372

Not Applicable

Modified to Read (changes shown in bold italics):

Part 1. Overview Information

Key Dates

Posted Date

March 25, 2021

Open Date (Earliest Submission Date)

May 05, 2021

Letter of Intent Due Date(s)

Not Applicable

The following table includes NIH standard due dates marked with an asterisk.

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

May 08, 2024

Due Dates for E.O. 12372

Not Applicable

Additionally, modifications have also been made to the following section:

Currently Reads:

Section IV. Application and Submission Information

2. Content and Form of Application Submission

PHS 398 Research Plan

2. Background and Significance: The application should clearly state a cancer related problem, its importance, and the potential benefits gained via proposed mitigation or solution.

4. Approach: Provide a detailed, rational plan for translation of the new method or technology that addresses a cancer problem. Indicate why it is ready to be translated. Provide preliminary data that support the study plan, feasibility, and approach to validation. For context, include a description of expected user groups and their environments.

Modified to Read (changes shown in bold italics):

Section IV. Application and Submission Information

2. Content and Form of Application Submission

PHS 398 Research Plan

2. Background and Significance: The application should clearly state a biomedical related problem, its importance, and the potential benefits gained via proposed mitigation or solution.

4. Approach: Provide a detailed, rational plan for translation of the new method or technology that addresses a biomedical problem. Indicate why it is ready to be translated. Provide preliminary data that support the study plan, feasibility, and approach to validation. For context, include a description of expected user groups and their environments

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Miguel R. Ossandon, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-5714
Email: [email protected]

Christopher Hartshorn, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-781-3315
Email: [email protected]